Literature DB >> 3156656

Erythema nodosum and circulating immune complexes in acne fulminans after treatment with isotretinoin.

J K Kellett, M H Beck, R J Chalmers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156656      PMCID: PMC1418564          DOI: 10.1136/bmj.290.6471.820

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  Acne fulminans with arthritis in identical twins treated with isotretinoin.

Authors:  C R Darley; H L Currey; H Baker
Journal:  J R Soc Med       Date:  1984-04       Impact factor: 5.344

2.  Flare of cystic acne from oral isotretinoin.

Authors:  R A Katz; H Jorgensen; T P Nigra
Journal:  J Am Acad Dermatol       Date:  1983-01       Impact factor: 11.527

3.  Pyogenic granuloma-like acne lesions during isotretinoin therapy.

Authors:  J H Exner; S Dahod; P E Pochi
Journal:  Arch Dermatol       Date:  1983-10

4.  Acne arthralgia.

Authors:  J J Lane JMLeyden; R J Spiegel
Journal:  J Bone Joint Surg Am       Date:  1976-07       Impact factor: 5.284

  4 in total
  5 in total

Review 1.  Acne: a review of immunologic and microbiologic factors.

Authors:  C G Burkhart; C N Burkhart; P F Lehmann
Journal:  Postgrad Med J       Date:  1999-06       Impact factor: 2.401

2.  Severe ulcerated 'bodybuilding acne' caused by anabolic steroid use and exacerbated by isotretinoin.

Authors:  Verena Voelcker; Michael Sticherling; Jürgen Bauerschmitz
Journal:  Int Wound J       Date:  2010-06       Impact factor: 3.315

Review 3.  [Clinical variants of acne].

Authors:  T Jansen; S Grabbe; G Plewig
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

4.  Osteomyelitis-like bone lesions in acne fulminans.

Authors:  S L Pauli; T Valkeakari; L Räsänen; M L Tuomi; T Reunala
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

Review 5.  Adverse reactions to oral retinoids. An update.

Authors:  C M Mills; R Marks
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.